Format

Send to

Choose Destination
See comment in PubMed Commons below
J Exp Clin Cancer Res. 2010 Feb 24;29:15. doi: 10.1186/1756-9966-29-15.

Plasma pharmacokinetics after combined therapy of gemcitabine and oral S-1 for unresectable pancreatic cancer.

Author information

1
Department of Surgical Oncology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan. bunzo@med.osaka-cu.ac.jp

Abstract

BACKGROUND:

The combination of gemcitabine (GEM) and S-1, an oral 5-fluorouracil (5-FU) derivative, has been shown to be a promising regimen for patients with unresectable pancreatic cancer.

METHODS:

Six patients with advanced pancreatic cancer were enrolled in this pharmacokinetics (PK) study. These patients were treated by oral administration of S-1 30 mg/m2 twice daily for 28 consecutive days, followed by a 14-day rest period and intravenous administration of GEM 800 mg/m2 on days 1, 15 and 29 of each course. The PK parameters of GEM and/or 5-FU after GEM single-administration, S-1 single-administration, and co-administration of GEM with pre-administration of S-1 at 2-h intervals were analyzed.

RESULTS:

The maximum concentration (Cmax), the area under the curve from the drug administration to the infinite time (AUCinf), and the elimination half-life (T1/2) of GEM were not significantly different between GEM administration with and without S-1. The Cmax, AUCinf, T1/2, and the time required to reach Cmax (Tmax) were not significantly different between S-1 administration with and without GEM.

CONCLUSION:

There were no interactions between GEM and S-1 regarding plasma PK of GEM and 5-FU.

PMID:
20181235
PMCID:
PMC2838818
DOI:
10.1186/1756-9966-29-15
[Indexed for MEDLINE]
Free PMC Article
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for BioMed Central Icon for PubMed Central
    Loading ...
    Support Center